Celltrion USA expands access to Zymfentra

South Korea-based biosimilar drug developer Celltrion’s (Kosdaq: 068270) US subsidiary has signed an agreement with pharmacy benefit managers (PBMs) Cigna Healthcare, and Express Scripts that will help expand patient access to Zymfentra (infliximab-dyyb).

Referencing Johnson & Johnson’s (NYSE: JNJ) Remsima and Inflectra brands, Celltrion noted that Zymfentra is the first and only US Food and Drug Administration (FDA)-approved subcutaneous infliximab.

The agreement, effective August 1, 2024, lists Zymfentra as the preferred medication on the Cigna’s medical formulary serving 16.1 million insured lives.